Lactic Acidosis: Recognition, Kinetics, and Associated Prognosis

Critical Care Clinics

Volumn 26, Issue 2, 2010, Pages 255-283

  Vernon, Christopher ^a   LeTourneau, Jennifer L ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Critical care; Lactic acidosis; Metabolic diseases; Mitochondria; Prognosis; Shock

Indexed keywords

ADRENALIN; ALCOHOL; ATORVASTATIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOTIN; DIETHYLENE GLYCOL; ETHYLENE GLYCOL; IRON; ISONIAZID; LACTATE DEHYDROGENASE; LACTIC ACID; LACTULOSE; LINEZOLID; METFORMIN; METHANOL; NALIDIXIC ACID; NICOTINIC ACID; PARACETAMOL; PROPOFOL; PYRUVIC ACID; RINGER LACTATE SOLUTION; RITODRINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SALAZOSULFAPYRIDINE; SALBUTAMOL; SALICYLIC ACID; SIMVASTATIN; TERBUTALINE; THIAMINE; UNINDEXED DRUG;

ANAEROBIC METABOLISM; ARTERIAL BLOOD; BIOSYNTHESIS; CLEARANCE; CLINICAL TRIAL; CRITICAL ILLNESS; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MEGADOSE; EMERGENCY WARD; HEPATIC ENCEPHALOPATHY; HUMAN; HYPOXIA; INTENSIVE CARE; INTENSIVE CARE UNIT; ISCHEMIA; KEARNS SAYRE SYNDROME; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIVER FAILURE; LOW DRUG DOSE; MALARIA; MALIGNANT NEOPLASTIC DISEASE; MELAS SYNDROME; MERRF SYNDROME; METABOLIC ACIDOSIS; MORTALITY; NONHUMAN; PEARSON SYNDROME; PRIORITY JOURNAL; PROGNOSIS; RESUSCITATION; REVIEW; SEPSIS; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; VENOUS BLOOD;

ACIDOSIS, LACTIC; HUMANS; LACTIC ACID; PROGNOSIS;

EID: 77951146321     PISSN: 07490704     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccc.2009.12.007     Document Type: Review

References (218)

1. Kompanje E.J., Jansen T.C., van der Hoven B., et al. The first demonstration of lactic acid in human blood in shock by Johann Joseph Scherer (1814-1869) in January 1843. Intensive Care Med 2007, 33(11):1967-1971.
2. Fletcher W.M. Lactic acid in amphibian muscle. J Physiol 1907, 35(4):247-309.
3. Huckabee W.E. Relationship of pyruvate and lactate during anaerobic metabolism. IV. Local tissue components of total body O2-debt. Am J Physiol 1959, 196(2):253-260.
4. Huckabee W.E. Relationships of pyruvate and lactate during anaerobic metabolism. III. Effect of breathing low-oxygen gases. J Clin Invest 1958, 37(2):264-271.
5. Huckabee W.E. Relationships of pyruvate and lactate during anaerobic metabolism. II. Exercise and formation of O-debt. J Clin Invest 1958, 37(2):255-263.
6. Huckabee W.E. Relationships of pyruvate and lactate during anaerobic metabolism. I. Effects of infusion of pyruvate or glucose and of hyperventilation. J Clin Invest 1958, 37(2):244-254.
7. Huckabee W.E. Abnormal resting blood lactate. I. The significance of hyperlactatemia in hospitalized patients. Am J Med 1961, 30:840-848.
8. Woods H.F., Cohen R. Clinical and biochemical aspects of lactic acidosis 1976, Blackwell Scientific, Oxford.
9. Gladden L.B. Lactate metabolism: a new paradigm for the third millennium. J Physiol 2004, 558(Pt 1):5-30.
10. Philp A., Macdonald A.L., Watt P.W. Lactate-a signal coordinating cell and systemic function. J Exp Biol 2005, 208(Pt 24):4561-4575.
11. Levy B. Lactate and shock state: the metabolic view. Curr Opin Crit Care 2006, 12(4):315-321.
12. De Backer D., Creteur J., Zhang H., et al. Lactate production by the lungs in acute lung injury. Am J Respir Crit Care Med 1997, 156(4 Pt 1):1099-1104.
13. Borregaard N., Herlin T. Energy metabolism of human neutrophils during phagocytosis. J Clin Invest 1982, 70(3):550-557.
14. Mizock B.A. Hyperlactatemia in acute liver failure: decreased clearance versus increased production. Crit Care Med 2001, 29(11):2225-2226.
15. De Backer D., Creteur J., Silva E., et al. The hepatosplanchnic area is not a common source of lactate in patients with severe sepsis. Crit Care Med 2001, 29(2):256-261.
16. Levraut J., Ciebiera J.P., Chave S., et al. Mild hyperlactatemia in stable septic patients is due to impaired lactate clearance rather than overproduction. Am J Respir Crit Care Med 1998, 157(4 Pt 1):1021-1026.
17. Bellomo R. Bench-to-bedside review: lactate and the kidney. Crit Care 2002, 6(4):322-326.
18. Bihari D., Gimson A.E., Lindridge J., et al. Lactic acidosis in fulminant hepatic failure. Some aspects of pathogenesis and prognosis. J Hepatol 1985, 1(4):405-416.
19. Vary T.C. Sepsis-induced alterations in pyruvate dehydrogenase complex activity in rat skeletal muscle: effects on plasma lactate. Shock 1996, 6(2):89-94.
20. Levy B., Sadoune L.O., Gelot A.M., et al. Evolution of lactate/pyruvate and arterial ketone body ratios in the early course of catecholamine-treated septic shock. Crit Care Med 2000, 28(1):114-119.
21. Revelly J.P., Tappy L., Martinez A., et al. Lactate and glucose metabolism in severe sepsis and cardiogenic shock. Crit Care Med 2005, 33(10):2235-2240.
22. Dellinger R.P., Levy M.M., Carlet J.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008, 36(1):296-327.
23. Weil M.H., Afifi A.A. Experimental and clinical studies on lactate and pyruvate as indicators of the severity of acute circulatory failure (shock). Circulation 1970, 41(6):989-1001.
24. Cady L.D., Weil M.H., Afifi A.A., et al. Quantitation of severity of critical illness with special reference to blood lactate. Crit Care Med 1973, 1(2):75-80.
25. Stacpoole P.W., Wright E.C., Baumgartner T.G., et al. Natural history and course of acquired lactic acidosis in adults. DCA-Lactic Acidosis Study Group. Am J Med 1994, 97(1):47-54.
26. Trzeciak S., Dellinger R.P., Chansky M.E., et al. Serum lactate as a predictor of mortality in patients with infection. Intensive Care Med 2007, 33(6):970-977.
27. Shapiro N.I., Howell M.D., Talmor D., et al. Serum lactate as a predictor of mortality in emergency department patients with infection. Ann Emerg Med 2005, 45(5):524-528.
28. Shapiro N.I., Howell M.D., Donnino M., et al. Occult hypoperfusion and mortality in patients with suspected infection. Intensive Care Med 2007, 33(11):1892-1899.
29. Mikkelsen M.E., Miltiades A.N., Gaieski D.F., et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med 2009, 37(5):1670-1677.
30. Jansen T.C., van Bommel J., Woodward R., et al. Association between blood lactate levels, sequential organ failure assessment subscores, and 28-day mortality during early and late intensive care unit stay: a retrospective observational study. Crit Care Med 2009, 37(8):2369-2374.
31. Chuang C.K., Wang T.J., Yeung C.Y., et al. Interference and blood sample preparation for a pyruvate enzymatic assay. Clin Biochem 2006, 39(1):74-77.
32. Suistomaa M., Ruokonen E., Kari A., et al. Time-pattern of lactate and lactate to pyruvate ratio in the first 24 hours of intensive care emergency admissions. Shock 2000, 14(1):8-12.
33. Bakker J., Coffernils M., Leon M., et al. Blood lactate levels are superior to oxygen-derived variables in predicting outcome in human septic shock. Chest 1991, 99(4):956-962.
34. Bakker J., Gris P., Coffernils M., et al. Serial blood lactate levels can predict the development of multiple organ failure following septic shock. Am J Surg 1996, 171(2):221-226.
35. Abramson D., Scalea T.M., Hitchcock R., et al. Lactate clearance and survival following injury. J Trauma 1993, 35(4):584-588. [discussion: 588-9].
36. McNelis J., Marini C.P., Jurkiewicz A., et al. Prolonged lactate clearance is associated with increased mortality in the surgical intensive care unit. Am J Surg 2001, 182(5):481-485.
37. Husain F.A., Martin M.J., Mullenix P.S., et al. Serum lactate and base deficit as predictors of mortality and morbidity. Am J Surg 2003, 185(5):485-491.
38. Nguyen H.B., Rivers E.P., Knoblich B.P., et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med 2004, 32(8):1637-1642.
39. Stacpoole P.W., Nagaraja N.V., Hutson A.D. Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 2003, 43(7):683-691.
40. Stacpoole P.W., Kerr D.S., Barnes C., et al. Controlled clinical trial of dichloroacetate for treatment of congenital lactic acidosis in children. Pediatrics 2006, 117(5):1519-1531.
41. Bersin R.M., Stacpoole P.W. Dichloroacetate as metabolic therapy for myocardial ischemia and failure. Am Heart J 1997, 134(5 Pt 1):841-855.
42. Stacpoole P.W., Lorenz A.C., Thomas R.G., et al. Dichloroacetate in the treatment of lactic acidosis. Ann Intern Med 1988, 108(1):58-63.
43. Stacpoole P.W., Wright E.C., Baumgartner T.G., et al. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med 1992, 327(22):1564-1569.
44. Gallagher E.J., Rodriguez K., Touger M. Agreement between peripheral venous and arterial lactate levels. Ann Emerg Med 1997, 29(4):479-483.
45. Lavery R.F., Livingston D.H., Tortella B.J., et al. The utility of venous lactate to triage injured patients in the trauma center. J Am Coll Surg 2000, 190(6):656-664.
46. Marko P., Gabrielli A., Caruso L.J. Too much lactate or too little liver?. J Clin Anesth 2004, 16(5):389-395.
47. Noritomi D.T., Soriano F.G., Kellum J.A., et al. Metabolic acidosis in patients with severe sepsis and septic shock: a longitudinal quantitative study. Crit Care Med 2009, 37(10):2733-2739.
48. Didwania A., Miller J., Kassel D., et al. Effect of intravenous lactated Ringer's solution infusion on the circulating lactate concentration: Part 3. Results of a prospective, randomized, double-blind, placebo-controlled trial. Crit Care Med 1997, 25(11):1851-1854.
49. Warburg O. On the origin of cancer cells. Science 1956, 123(3191):309-314.
50. Baysal B.E., Ferrell R.E., Willett-Brozick J.E., et al. Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 2000, 287(5454):848-851.
51. Tomlinson I.P., Alam N.A., Rowan A.J., et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet 2002, 30(4):406-410.
52. Bellance N., Lestienne P., Rossignol R. Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front Biosci 2009, 14:4015-4034.
53. Friedenberg A.S., Brandoff D.E., Schiffman F.J. Type B lactic acidosis as a severe metabolic complication in lymphoma and leukemia: a case series from a single institution and literature review. Medicine (Baltimore) 2007, 86(4):225-232.
54. Colombo G.M., Del Vecchio L.R., Sacco T., et al. Fatal lactic acidosis due to widespread diffusion of melanoma. Minerva Med 2006, 97(3):295.
55. Manuel B., Suresh V., Saphwat E. Refractory metabolic acidosis in small cell cancer of the lung. South Med J 2006, 99(7):782-783.
56. Field M., Block J.B., Levin R., et al. Significance of blood lactate elevations among patients with acute leukemia and other neoplastic proliferative disorders. Am J Med 1966, 40:528-547.
57. Ustun C., Fall P., Szerlip H.M., et al. Multiple myeloma associated with lactic acidosis. Leuk Lymphoma 2002, 43(12):2395-2397.
58. Kachel R.G. Metastatic reticulum cell sarcoma and lactic acidosis. Cancer 1975, 36(6):2056-2059.
59. Varanasi U.R., Carr B., Simpson D.P. Lactic acidosis associated with metastatic breast carcinoma. Cancer Treat Rep 1980, 64(12):1283-1285.
60. Colman L.K., Baker T.M. Lactic acidosis with extensive oat cell carcinoma of the lung-not necessarily a poor prognostic sign: case report. Mil Med 1983, 148(5):440.
61. Cheng J.C., Esparza S.D., Knez V.M., et al. Severe lactic acidosis in a 14-year-old female with metastatic undifferentiated carcinoma of unknown primary. J Pediatr Hematol Oncol 2004, 26(11):780-782.
62. Wall B.M., Mansour N., Cooke C.R. Acute fulminant lactic acidosis complicating metastatic cholangiocarcinoma. Am J Med Sci 2000, 319(2):126-129.
63. Bischof T., Gunthard H., Straumann E., et al. Schweiz Med Wochenschr 1997, 127(7):261-265. [in German].
64. Sillos E.M., Shenep J.L., Burghen G.A., et al. Lactic acidosis: a metabolic complication of hematologic malignancies: case report and review of the literature. Cancer 2001, 92(9):2237-2246.
65. Coleman R.A., Sommerville H.M., Friedman H.S., et al. Insulin therapy for ketolactic acidosis complicating malignancy. J Pediatr 1982, 100(4):584-587.
66. Fraley D.S., Adler S., Bruns F.J., et al. Stimulation of lactate production by administration of bicarbonate in a patient with a solid neoplasm and lactic acidosis. N Engl J Med 1980, 303(19):1100-1102.
67. Hurtado F.J., Gutierrez A.M., Silva N., et al. Role of tissue hypoxia as the mechanism of lactic acidosis during E. coli endotoxemia. J Appl Physiol 1992, 72(5):1895-1901.
68. Gore D.C., Jahoor F., Hibbert J.M., et al. Lactic acidosis during sepsis is related to increased pyruvate production, not deficits in tissue oxygen availability. Ann Surg 1996, 224(1):97-102.
69. Vary T.C. Increased pyruvate dehydrogenase kinase activity in response to sepsis. Am J Physiol 1991, 260(5 Pt 1):E669-E674.
70. Brown S.D., Clark C., Gutierrez G. Pulmonary lactate release in patients with sepsis and the adult respiratory distress syndrome. J Crit Care 1996, 11(1):2-8.
71. Severin P.N., Uhing M.R., Beno D.W., et al. Endotoxin-induced hyperlactatemia results from decreased lactate clearance in hemodynamically stable rats. Crit Care Med 2002, 30(11):2509-2514.
72. Funk G.C., Doberer D., Kneidinger N., et al. Acid-base disturbances in critically ill patients with cirrhosis. Liver Int 2007, 27(7):901-909.
73. Tsai M.H., Chen Y.C., Lien J.M., et al. Hemodynamics and metabolic studies on septic shock in patients with acute liver failure. J Crit Care 2008, 23(4):468-472.
74. Bernal W., Donaldson N., Wyncoll D., et al. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002, 359(9306):558-563.
75. Burcham P.C., Harman A.W. Acetaminophen toxicity results in site-specific mitochondrial damage in isolated mouse hepatocytes. J Biol Chem 1991, 266(8):5049-5054.
76. Donnelly P.J., Walker R.M., Racz W.J. Inhibition of mitochondrial respiration in vivo is an early event in acetaminophen-induced hepatotoxicity. Arch Toxicol 1994, 68(2):110-118.
77. Esterline R.L., Ray S.D., Ji S. Reversible and irreversible inhibition of hepatic mitochondrial respiration by acetaminophen and its toxic metabolite, N-acetyl-p-benzoquinoneimine (NAPQI). Biochem Pharmacol 1989, 38(14):2387-2390.
78. Kraut J.A., Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. Clin J Am Soc Nephrol 2008, 3(1):208-225.
79. Brooks D.E., Wallace K.L. Acute propylene glycol ingestion. J Toxicol Clin Toxicol 2002, 40(4):513-516.
80. Wilson K.C., Reardon C., Theodore A.C., et al. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and prospective, observational pilot study. Chest 2005, 128(3):1674-1681.
81. Demey H.E., Daelemans R.A., Verpooten G.A., et al. Propylene glycol-induced side effects during intravenous nitroglycerin therapy. Intensive Care Med 1988, 14(3):221-226.
82. Bedichek E., Kirschbaum B. A case of propylene glycol toxic reaction associated with etomidate infusion. Arch Intern Med 1991, 151(11):2297-2298.
83. Miller M.A., Forni A., Yogaratnam D. Propylene glycol-induced lactic acidosis in a patient receiving continuous infusion pentobarbital. Ann Pharmacother 2008, 42(10):1502-1506.
84. Yahwak J.A., Riker R.R., Fraser G.L., et al. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. Pharmacotherapy 2008, 28(8):984-991.
85. Parker M.G., Fraser G.L., Watson D.M., et al. Removal of propylene glycol and correction of increased osmolar gap by hemodialysis in a patient on high dose lorazepam infusion therapy. Intensive Care Med 2002, 28(1):81-84.
86. Zar T., Yusufzai I., Sullivan A., et al. Acute kidney injury, hyperosmolality and metabolic acidosis associated with lorazepam. Nat Clin Pract Nephrol 2007, 3(9):515-520.
87. Shibuyama S., Gevorkyan A., Yoo U., et al. Understanding and avoiding antiretroviral adverse events. Curr Pharm Des 2006, 12(9):1075-1090.
88. ter Hofstede H.J., Willems H.L., Koopmans P.P. Serum L-lactate and pyruvate in HIV-infected patients with and without presumed NRTI-related adverse events compared to healthy volunteers. J Clin Virol 2004, 29(1):44-50.
89. Birkus G., Hitchcock M.J., Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002, 46(3):716-723.
90. Moyle G. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity. Clin Ther 2000, 22(8):911-936. [discussion: 898].
91. Hocqueloux L., Alberti C., Feugeas J.P., et al. Prevalence, risk factors and outcome of hyperlactataemia in HIV-infected patients. HIV Med 2003, 4(1):18-23.
92. Lactic Acidosis International Study Group. Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy. AIDS 2007, 21(18):2455-2464.
93. Schambelan M., Benson C.A., Carr A., et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002, 31(3):257-275.
94. Cote H.C., Brumme Z.L., Craib K.J., et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002, 346(11):811-820.
95. Misbin R.I. Phenformin-associated lactic acidosis: pathogenesis and treatment. Ann Intern Med 1977, 87(5):591-595.
96. Owen M.R., Doran E., Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000, 348(Pt 3):607-614.
97. Dell'aglio D.M., Perino L.J., Kazzi Z., et al. Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann Emerg Med 2009, 54(6):818-823.
98. Misbin R.I., Green L., Stadel B.V., et al. Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 1998, 338(4):265-266.
99. Stades A.M., Heikens J.T., Erkelens D.W., et al. Metformin and lactic acidosis: cause or coincidence? A review of case reports. J Intern Med 2004, 255(2):179-187.
100. Seidowsky A., Nseir S., Houdret N., et al. Metformin-associated lactic acidosis: a prognostic and therapeutic study. Crit Care Med 2009, 37(7):2191-2196.
101. Fodale V., La Monaca E. Propofol infusion syndrome: an overview of a perplexing disease. Drug Saf 2008, 31(4):293-303.
102. Kang T.M. Propofol infusion syndrome in critically ill patients. Ann Pharmacother 2002, 36(9):1453-1456.
103. Merz T.M., Regli B., Rothen H.U., et al. Propofol infusion syndrome-a fatal case at a low infusion rate. Anesth Analg 2006, 103(4):1050.
104. Mehta N., DeMunter C., Habibi P., et al. Short-term propofol infusions in children. Lancet 1999, 354(9181):866-867.
105. Wolf A., Weir P., Segar P., et al. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet 2001, 357(9256):606-607.
106. Motsch J., Roggenbach J. Anaesthesist 2004, 53(10):1009-1022. [in German].
107. Pharmacia & Upjohn. Zyvox (linezolid) package insert (Revised July 2008). Available at:, Accessed August 24, 2009. http://media.pfizer.com/files/products/uspi_zyvox.pdf.
108. Narita M., Tsuji B.T., Yu V.L. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy 2007, 27(8):1189-1197.
109. Apodaca A.A., Rakita R.M. Linezolid-induced lactic acidosis. N Engl J Med 2003, 348(1):86-87.
110. Kopterides P., Papadomichelakis E., Armaganidis A. Linezolid use associated with lactic acidosis. Scand J Infect Dis 2005, 37(2):153-154.
111. Wiener M., Guo Y., Patel G., et al. Lactic acidosis after treatment with linezolid. Infection 2007, 35(4):278-281.
112. De Vriese A.S., Coster R.V., Smet J., et al. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis 2006, 42(8):1111-1117.
113. Palenzuela L., Hahn N.M., Nelson R.P., et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis?. Clin Infect Dis 2005, 40(12):e113-e116.
114. Pea F., Scudeller L., Lugano M., et al. Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient. Clin Infect Dis 2006, 42(3):434-435.
115. Bernard L., Stern R., Lew D., et al. Serotonin syndrome after concomitant treatment with linezolid and citalopram. Clin Infect Dis 2003, 36(9):1197.
116. Madias N.E., Goorno W.E., Herson S. Severe lactic acidosis as a presenting feature of pheochromocytoma. Am J Kidney Dis 1987, 10(3):250-253.
117. Bundgaard H., Kjeldsen K., Suarez Krabbe K., et al. Endotoxemia stimulates skeletal muscle Na+-K+-ATPase and raises blood lactate under aerobic conditions in humans. Am J Physiol Heart Circ Physiol 2003, 284(3):H1028-H1034.
118. James J.H., Luchette F.A., McCarter F.D., et al. Lactate is an unreliable indicator of tissue hypoxia in injury or sepsis. Lancet 1999, 354(9177):505-508.
119. Levy B., Mansart A., Bollaert P.E., et al. Effects of epinephrine and norepinephrine on hemodynamics, oxidative metabolism, and organ energetics in endotoxemic rats. Intensive Care Med 2003, 29(2):292-300.
120. Eichenholz A., Mulhausen R.O., Redleaf P.S. Nature of acid-base disturbance in salicylate intoxication. Metabolism 1963, 12(2):164-175.
121. Singer R.B. The acid-base disturbance in salicylate intoxication. Medicine (Baltimore) 1954, 33(1):1-13.
122. Fromenty B., Pessayre D. Inhibition of mitochondrial beta-oxidation as a mechanism of hepatotoxicity. Pharmacol Ther 1995, 67(1):101-154.
123. Vessey D.A., Hu J., Kelley M. Interaction of salicylate and ibuprofen with the carboxylic acid: CoA ligases from bovine liver mitochondria. J Biochem Toxicol 1996, 11(2):73-78.
124. Kaplan E.H., Kennedy J., Davis J. Effects of salicylate and other benzoates on oxidative enzymes of the tricarboxylic acid cycle in rat tissue homogenates. Arch Biochem Biophys 1954, 51(1):47-61.
125. Haas R., Parker W.D., Stumpf D., et al. Salicylate-induced loose coupling: protonmotive force measurements. Biochem Pharmacol 1985, 34(6):900-902.
126. Tarui S., Kono N., Kuwajima M., et al. Hereditary and acquired abnormalities in erythrocyte phosphofructokinase activity: the close association with altered 2,3-diphosphoglycerate levels. Hemoglobin 1980, 4(5-6):581-592.
127. Sallis R.E. Management of salicylate toxicity. Am Fam Physician 1989, 39(3):265-270.
128. Klotz U. Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid. Clin Pharmacokinet 1985, 10(4):285-302.
129. Dunn R.J. Massive sulfasalazine and paracetamol ingestion causing acidosis, hyperglycemia, coagulopathy, and methemoglobinemia. J Toxicol Clin Toxicol 1998, 36(3):239-242.
130. Alvarez F.G., Guntupalli K.K. Isoniazid overdose: four case reports and review of the literature. Intensive Care Med 1995, 21(8):641-644.
131. Goli A.K., Goli S.A., Byrd R.P., et al. Simvastatin-induced lactic acidosis: a rare adverse reaction?. Clin Pharmacol Ther 2002, 72(4):461-464.
132. Neale R., Reynolds T.M., Saweirs W. Statin precipitated lactic acidosis?. J Clin Pathol 2004, 57(9):989-990.
133. Earthman T.P., Odom L., Mullins C.A. Lactic acidosis associated with high-dose niacin therapy. South Med J 1991, 84(4):496-497.
134. Gustafson P.R. Profound lactic acidosis in a young woman treated with nalidixic acid. Tex Med 1985, 81(2):53-54.
135. Maher J.R., Speyer J.F., Levine M. Studies on the mode of action of isoniazid. I. The role of trace metals in the inhibition of bovine liver catalase by isoniazid. Am Rev Tuberc 1958, 77(3):501-505.
136. Ghirlanda G., Oradei A., Manto A., et al. Evidence of plasma CoQ10-lowering effect by HMG-CoA reductase inhibitors: a double-blind, placebo-controlled study. J Clin Pharmacol 1993, 33(3):226-229.
137. Mann N.S., Russman H.B., Mann S.K., et al. Lactulose and severe lactic acidosis. Ann Intern Med 1985, 103(4):637.
138. Mukunda B.N. Lactic acidosis caused by thiamine deficiency in a pregnant alcoholic patient. Am J Med Sci 1999, 317(4):261-262.
139. Cho Y.P., Kim K., Han M.S., et al. Severe lactic acidosis and thiamine deficiency during total parenteral nutrition-case report. Hepatogastroenterology 2004, 51(55):253-255.
140. Klein M., Weksler N., Gurman G.M. Fatal metabolic acidosis caused by thiamine deficiency. J Emerg Med 2004, 26(3):301-303.
141. Fattal-Valevski A., Kesler A., Sela B.A., et al. Outbreak of life-threatening thiamine deficiency in infants in Israel caused by a defective soy-based formula. Pediatrics 2005, 115(2):e233-e238.
142. Van den Berg P.J., Bijlstra P.J., Brekelmans G.J. Thiamine deficiency as a single cause of life-threatening lactic acidosis in a patient with acute axonal polyneuropathy. Intern Emerg Med 2009, 4(6):539-541.
143. Song Q., Singleton C.K. Mitochondria from cultured cells derived from normal and thiamine-responsive megaloblastic anemia individuals efficiently import thiamine diphosphate. BMC Biochem 2002, 3:8.
144. Singleton C.K., Martin P.R. Molecular mechanisms of thiamine utilization. Curr Mol Med 2001, 1(2):197-207.
145. Hakim A.M. The induction and reversibility of cerebral acidosis in thiamine deficiency. Ann Neurol 1984, 16(6):673-679.
146. Berthon H.A., Kuchel P.W., Nixon P.F. High control coefficient of transketolase in the nonoxidative pentose phosphate pathway of human erythrocytes: NMR, antibody, and computer simulation studies. Biochemistry 1992, 31(51):12792-12798.
147. Navarro D., Zwingmann C., Chatauret N., et al. Glucose loading precipitates focal lactic acidosis in the vulnerable medial thalamus of thiamine-deficient rats. Metab Brain Dis 2008, 23(1):115-122.
148. Visser C.M., Kellogg R.M. Biotin. Its place in evolution. J Mol Evol 1978, 11(2):171-187.
149. Wessman G.E., Werkman C.H. Biotin in the assimilation of heavy carbon in Oxalacetate. Arch Biochem 1950, 26(2):214-218.
150. Sydenstricker V.P., Singal S.A., Briggs A.P., et al. Preliminary observations on " Egg White Injury" in man and its cure with a biotin concentrate. Science 1942, 95(2459):176-177.
151. Gyorgy P., Rose C.S. Cure of egg-white injury in rats by the " Toxic" fraction (avidin) of egg white given parenterally. Science 1941, 94(2437):261-262.
152. Carlson G.L., Williams N., Barber D., et al. Biotin deficiency complicating long-term total parenteral nutrition in an adult patient. Clin Nutr 1995, 14(3):186-190.
153. Mikati M.A., Zalloua P., Karam P., et al. Novel mutation causing partial biotinidase deficiency in a Syrian boy with infantile spasms and retardation. J Child Neurol 2006, 21(11):978-981.
154. Said H.M., Ortiz A., McCloud E., et al. Biotin uptake by human colonic epithelial NCM460 cells: a carrier-mediated process shared with pantothenic acid. Am J Physiol 1998, 275(5 Pt 1):C1365-C1371.
155. Moreadith R.W., Batshaw M.L., Ohnishi T., et al. Deficiency of the iron-sulfur clusters of mitochondrial reduced nicotinamide-adenine dinucleotide-ubiquinone oxidoreductase (complex I) in an infant with congenital lactic acidosis. J Clin Invest 1984, 74(3):685-697.
156. Mathews C.K., van Holde K.E. Biochemistry 1990, The Benjamin/Cummings Publishing Company, Redwood City (CA).
157. Fellman V. The GRACILE syndrome, a neonatal lethal metabolic disorder with iron overload. Blood Cells Mol Dis 2002, 29(3):444-450.
158. Finch C.A., Gollnick P.D., Hlastala M.P., et al. Lactic acidosis as a result of iron deficiency. J Clin Invest 1979, 64(1):129-137.
159. Wang Y.M., van Eys J. Nutritional significance of fructose and sugar alcohols. Annu Rev Nutr 1981, 1:437-475.
160. Wekell M.M., Hartman W.J., Dong F.M. Incidence of increased numbers of Clostridium perfringens in the intestinal tract of rats fed xylitol. J Nutr 1980, 110(10):2103-2108.
161. Craig G.M., Crane C.W. Lactic acidosis complicating liver failure after intravenous fructose. Br Med J 1971, 4(5781):211-212.
162. Batstone G.F., Alberti K.G., Dewar A.K. Reversible lactic acidosis associated with repeated intravenous infusions of sorbitol and ethanol. Postgrad Med J 1977, 53(623):567-569.
163. Korttila K., Mattila M.A. Increased serum concentrations of lactic, pyruvic and uric acid and bilibubin after postoperative xylitol infusion. Acta Anaesthesiol Scand 1979, 23(3):273-277.
164. Wang Y.M., King S.M., Patterson J.H., et al. Mechanism of xylitol toxicity in the rabbit. Metabolism 1973, 22(7):885-894.
165. Facts about strychnine. Emergency preparedness and response Available at:, Accessed August 24, 2009. http://www.bt.cdc.gov/agent/strychnine/basics/facts.asp.
166. Boyd R.E., Brennan P.T., Deng J.F., et al. Strychnine poisoning. Recovery from profound lactic acidosis, hyperthermia, and rhabdomyolysis. Am J Med 1983, 74(3):507-512.
167. Snow R.W., Guerra C.A., Noor A.M., et al. The global distribution of clinical episodes of Plasmodium falciparum malaria. Nature 2005, 434(7030):214-217.
168. Krishna S., Waller D.W., ter Kuile F., et al. Lactic acidosis and hypoglycaemia in children with severe malaria: pathophysiological and prognostic significance. Trans R Soc Trop Med Hyg 1994, 88(1):67-73.
169. Molyneux M.E., Looareesuwan S., Menzies I.S., et al. Reduced hepatic blood flow and intestinal malabsorption in severe falciparum malaria. Am J Trop Med Hyg 1989, 40(5):470-476.
170. Pukrittayakamee S., Krishna S., Ter Kuile F., et al. Alanine metabolism in acute falciparum malaria. Trop Med Int Health 2002, 7(11):911-918.
171. Mi-Ichi F., Takeo S., Takashima E., et al. Unique properties of respiratory chain in Plasmodium falciparum mitochondria. Adv Exp Med Biol 2003, 531:117-133.
172. Planche T., Agbenyega T., Bedu-Addo G., et al. A prospective comparison of malaria with other severe diseases in African children: prognosis and optimization of management. Clin Infect Dis 2003, 37(7):890-897.
173. Watt G., Jongsakul K., Ruangvirayuth R. A pilot study of N-acetylcysteine as adjunctive therapy for severe malaria. QJM 2002, 95(5):285-290.
174. Haas R., Stumpf D.A., Parks J.K., et al. Inhibitory effects of sodium valproate on oxidative phosphorylation. Neurology 1981, 31(11):1473-1476.
175. Ponchaut S., van Hoof F., Veitch K. Cytochrome aa3 depletion is the cause of the deficient mitochondrial respiration induced by chronic valproate administration. Biochem Pharmacol 1992, 43(3):644-647.
176. Ponchaut S., Van Hoof F., Veitch K. Valproate and cytochrome c oxidase deficiency. Eur J Pediatr 1995, 154(1):79.
177. Rumbach L., Cremel G., Marescaux C., et al. Succinate transport inhibition by valproate in rat renal mitochondria. Eur J Pharmacol 1989, 164(3):577-581.
178. Rumbach L., Mutet C., Cremel G., et al. Effects of sodium valproate on mitochondrial membranes: electron paramagnetic resonance and transmembrane protein movement studies. Mol Pharmacol 1986, 30(3):270-273.
179. Lin C.M., Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA. Metab Brain Dis 2007, 22(1):105-109.
180. Blayac D., Roch A., Michelet P., et al. Ann Fr Anesth Reanim 2004, 23(10):1007-1010. [in French].
181. Lam C.W., Lau C.H., Williams J.C., et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 1997, 156(7):562-564.
182. Jonsson S., O'Meara M., Young J.B. Acute cocaine poisoning. Importance of treating seizures and acidosis. Am J Med 1983, 75(6):1061-1064.
183. Isner J.M., Estes N.A., Thompson P.D., et al. Acute cardiac events temporally related to cocaine abuse. N Engl J Med 1986, 315(23):1438-1443.
184. Giammarco R.A. The athlete, cocaine, and lactic acidosis: a hypothesis. Am J Med Sci 1987, 294(6):412-414.
185. Burchell S.A., Ho H.C., Yu M., et al. Effects of methamphetamine on trauma patients: a cause of severe metabolic acidosis?. Crit Care Med 2000, 28(6):2112-2115.
186. Lan K.C., Lin Y.F., Yu F.C., et al. Clinical manifestations and prognostic features of acute methamphetamine intoxication. J Formos Med Assoc 1998, 97(8):528-533.
187. Thrash B., Karuppagounder S.S., Uthayathas S., et al. Neurotoxic effects of methamphetamine. Neurochem Res 2009, 35(1):171-179.
188. Tian C., Murrin L.C., Zheng J.C. Mitochondrial fragmentation is involved in methamphetamine-induced cell death in rat hippocampal neural progenitor cells. PLoS One 2009, 4(5):e5546.
189. Public health statement for cyanide [Cited 2007 September 4]. Available at:, Accessed August 24, 2009. http://www.atsdr.cdc.gov/toxprofiles/phs8.html.
190. El Hadri L., Chanas B., Ghanayem B.I. Comparative metabolism of methacrylonitrile and acrylonitrile to cyanide using cytochrome P4502E1 and microsomal epoxide hydrolase-null mice. Toxicol Appl Pharmacol 2005, 205(2):116-125.
191. Nessim S.J., Richardson R.M. Dialysis for thiocyanate intoxication: a case report and review of the literature. ASAIO J 2006, 52(4):479-481.
192. Johanning R.J., Zaske D.E., Tschida S.J., et al. A retrospective study of sodium nitroprusside use and assessment of the potential risk of cyanide poisoning. Pharmacotherapy 1995, 15(6):773-777.
193. Krab K., Slater E.C. Ferrocyanide as electron donor to cytochrome aa3. Cytochrome c requirement for oxygen uptake. Biochim Biophys Acta 1979, 547(1):58-69.
194. Chen K.K., Rose C.L. Nitrite and thiosulfate therapy in cyanide poisoning. J Am Med Assoc 1952, 149(2):113-119.
195. Baskin S.I., Horowitz A.M., Nealley E.W. The antidotal action of sodium nitrite and sodium thiosulfate against cyanide poisoning. J Clin Pharmacol 1992, 32(4):368-375.
196. Cottrell J.E., Casthely P., Brodie J.D., et al. Prevention of nitroprusside-induced cyanide toxicity with hydroxocobalamin. N Engl J Med 1978, 298(15):809-811.
197. Dobkin A.B. Anaesthesia with azeotropic mixture of nalothane and diethyl ether; the effect on acid-base balance, electrolyte balance, cardiac rhythm and circulatory dynamics. Br J Anaesth 1959, 31(2):53-65.
198. Kumar B., Kumar A., Pandey B.N., et al. Role of mitochondrial oxidative stress in the apoptosis induced by diospyrin diethylether in human breast carcinoma (MCF-7) cells. Mol Cell Biochem 2009, 320(1-2):185-195.
199. Valik D. Encephalopathy, lactic acidosis, hyperammonaemia and 5-fluorouracil toxicity. Br J Cancer 1998, 77(10):1710-1712.
200. Ito T. Children's toxicology from bench to bed-liver injury (1): drug-induced metabolic disturbance-toxicity of 5-FU for pyrimidine metabolic disorders and pivalic acid for carnitine metabolism. J Toxicol Sci 2009, 34(Suppl 2):SP217-SP222.
201. Zelickson A.S., Mottaz J., Weiss L.W. Effects of topical fluorouracil on normal skin. Arch Dermatol 1975, 111(10):1301-1306.
202. Noordhuis P., Holwerda U., Van der Wilt C.L., et al. 5-Fluorouracil incorporation into RNA and DNA in relation to thymidylate synthase inhibition of human colorectal cancers. Ann Oncol 2004, 15(7):1025-1032.
203. DiMauro S., Schon E.A. Mitochondrial respiratory-chain diseases. N Engl J Med 2003, 348(26):2656-2668.
204. DiMauro S., Mancuso M. Mitochondrial diseases: therapeutic approaches. Biosci Rep 2007, 27(1-3):125-137.
205. Kaufmann P., Engelstad K., Wei Y., et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology 2006, 66(3):324-330.
206. van den Berghe G. Disorders of gluconeogenesis. J Inherit Metab Dis 1996, 19(4):470-477.
207. Robinson B.H. Lactic acidemia and mitochondrial disease. Mol Genet Metab 2006, 89(1-2):3-13.
208. Robinson B.H., Oei J., Saudubray J.M., et al. The French and North American phenotypes of pyruvate carboxylase deficiency, correlation with biotin containing protein by 3H-biotin incorporation, 35S-streptavidin labeling, and Northern blotting with a cloned cDNA probe. Am J Hum Genet 1987, 40(1):50-59.
209. Hamilton J., Rae M.D., Logan R.W., et al. A case of benign pyruvate carboxylase deficiency with normal development. J Inherit Metab Dis 1997, 20(3):401-403.
210. Morath M.A., Okun J.G., Muller I.B., et al. Neurodegeneration and chronic renal failure in methylmalonic aciduria-a pathophysiological approach. J Inherit Metab Dis 2008, 31(1):35-43.
211. Kolker S., Sauer S.W., Surtees R.A., et al. The aetiology of neurological complications of organic acidaemias-a role for the blood-brain barrier. J Inherit Metab Dis 2006, 29(6):701-704. [discussion: 705-6].
212. Thornalley P.J. Pharmacology of methylglyoxal: formation, modification of proteins and nucleic acids, and enzymatic detoxification-a role in pathogenesis and antiproliferative chemotherapy. Gen Pharmacol 1996, 27(4):565-573.
213. Uribarri J., Oh M.S., Carroll H.J. D-lactic acidosis. A review of clinical presentation, biochemical features, and pathophysiologic mechanisms. Medicine (Baltimore) 1998, 77(2):73-82.
214. Hudson M., Pocknee R., Mowat N.A. D-lactic acidosis in short bowel syndrome-an examination of possible mechanisms. Q J Med 1990, 74(274):157-163.
215. Oh M.S., Phelps K.R., Traube M., et al. D-lactic acidosis in a man with the short-bowel syndrome. N Engl J Med 1979, 301(5):249-252.
216. Halperin M.L., Kamel K.S. D-lactic acidosis: turning sugar into acids in the gastrointestinal tract. Kidney Int 1996, 49(1):1-8.
217. Zhang D.L., Jiang Z.W., Jiang J., et al. D-lactic acidosis secondary to short bowel syndrome. Postgrad Med J 2003, 79(928):110-112.
218. Brooks G.A. The lactate shuttle during exercise and recovery. Med Sci Sports Exerc 1986, 18:360-368.